JZYY(SH:600750) Ge Long Hui A P P·2026-01-23 08:47Core Viewpoint - Jiangzhong Pharmaceutical (600750.SH) reported its 2025 annual performance, highlighting a focus on brand building and core business consolidation despite structural industry pressures [1] Financial Performance - The company achieved operating revenue of 4.22 billion yuan, a year-on-year decrease of 4.87% [1] - The net profit attributable to shareholders reached 906 million yuan, reflecting a year-on-year increase of 14.96% [1] Strategic Initiatives - The company emphasized strengthening brand development and focusing on "big single products and strong categories" to solidify its core business foundation [1] - Marketing strategies were enriched, with a focus on optimizing cost structures and enhancing return on investment [1] - Lean manufacturing practices were deepened to promote cost reduction and efficiency improvement, contributing to enhanced profitability [1]